US2816925A
(en)
*
|
1955-10-07 |
1957-12-17 |
Du Pont |
Diamines
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
US5804381A
(en)
|
1996-10-03 |
1998-09-08 |
Cornell Research Foundation |
Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US4975964A
(en)
*
|
1989-06-27 |
1990-12-04 |
Hochstein Peter A |
Automatic turn off system
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
US6235525B1
(en)
|
1991-05-23 |
2001-05-22 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
|
US5543152A
(en)
*
|
1994-06-20 |
1996-08-06 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
EP0900380B1
(en)
|
1996-04-26 |
2003-07-09 |
Rijksuniversiteit te Leiden |
Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
|
AU728581B2
(en)
|
1996-09-13 |
2001-01-11 |
Lipoxen Limited |
Liposomes
|
CA2217550A1
(en)
*
|
1996-10-22 |
1998-04-22 |
F. Hoffmann-La Roche Ag |
Cationic lipids for gene therapy
|
EP0839912A1
(en)
|
1996-10-30 |
1998-05-06 |
Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) |
Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
|
US6210707B1
(en)
*
|
1996-11-12 |
2001-04-03 |
The Regents Of The University Of California |
Methods of forming protein-linked lipidic microparticles, and compositions thereof
|
US6074645A
(en)
|
1996-11-12 |
2000-06-13 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
KR20010024585A
(ko)
|
1997-11-06 |
2001-03-26 |
로셰 디아그노스틱스 게엠베하 |
종양-특이적 항원, 이들의 제조방법, 및 이들의 면역화 및진단에서의 용도
|
WO1999033500A2
(en)
*
|
1997-12-31 |
1999-07-08 |
Pharmasonics, Inc. |
Methods, systems, and kits for intravascular nucleic acid delivery
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
WO2000020029A1
(en)
|
1998-10-05 |
2000-04-13 |
Genzyme Corporation |
Genes differentially expressed in cancer cells to design cancer vaccines
|
US9034329B2
(en)
*
|
1999-02-22 |
2015-05-19 |
Georgetown University |
Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
|
US8617514B2
(en)
*
|
1999-02-22 |
2013-12-31 |
Georgetown University |
Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
|
US7311924B2
(en)
*
|
1999-04-01 |
2007-12-25 |
Hana Biosciences, Inc. |
Compositions and methods for treating cancer
|
MXPA01011250A
(es)
|
1999-05-06 |
2002-08-12 |
Univ Wake Forest |
Composiciones y metodos para identificar antigenos que producen una respuesta inmune.
|
US7094423B1
(en)
*
|
1999-07-15 |
2006-08-22 |
Inex Pharmaceuticals Corp. |
Methods for preparation of lipid-encapsulated therapeutic agents
|
AU4903101A
(en)
|
1999-11-30 |
2001-07-09 |
Cornell Research Foundation Inc. |
Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
|
US7462354B2
(en)
|
1999-12-28 |
2008-12-09 |
Pharmexa Inc. |
Method and system for optimizing minigenes and peptides encoded thereby
|
AU780064B2
(en)
|
1999-12-28 |
2005-02-24 |
Epimmune, Inc. |
Optimized minigenes and peptides encoded thereby
|
AU2001275294A1
(en)
|
2000-06-07 |
2001-12-17 |
Biosynexus Incorporated. |
Immunostimulatory RNA/DNA hybrid molecules
|
US6472176B2
(en)
|
2000-12-14 |
2002-10-29 |
Genvec, Inc. |
Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
|
CA2830887C
(en)
|
2001-06-05 |
2016-11-29 |
Curevac Gmbh |
Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
AUPS054702A0
(en)
|
2002-02-14 |
2002-03-07 |
Immunaid Pty Ltd |
Cancer therapy
|
CA2489296A1
(en)
|
2002-06-13 |
2003-12-24 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Methods for the identification of allo-antigens and their use for cancer therapy and transplantation
|
DK2286795T3
(en)
*
|
2002-06-26 |
2017-02-06 |
Syncore Biotechnology Co Ltd |
PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
|
JP4722481B2
(ja)
*
|
2002-06-28 |
2011-07-13 |
プロティバ バイオセラピューティクス リミテッド |
リポソーム製造方法および装置
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
CN100340289C
(zh)
*
|
2002-07-05 |
2007-10-03 |
利普生技术有限公司 |
增强核酸接种免疫应答的方法
|
DE10344799A1
(de)
|
2003-09-26 |
2005-04-14 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
AU2004283464B8
(en)
|
2003-10-15 |
2011-04-14 |
Syncore Biotechnology Co., Ltd |
Method of administering cationic liposomes comprising an active drug
|
BRPI0415533A
(pt)
|
2003-10-24 |
2006-12-26 |
Immunaid Pty Ltd |
método de terapia
|
US7303881B2
(en)
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
DE102004023187A1
(de)
|
2004-05-11 |
2005-12-01 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
EP1793865A4
(en)
*
|
2004-08-05 |
2009-05-13 |
Baylor Res Inst |
GENETIC OR DRUG DELIVERY SYSTEM
|
AU2005306075A1
(en)
*
|
2004-11-19 |
2006-05-26 |
Novosom Ag |
Improvements in or relating to pharmaceutical compositions for local administration
|
DE102004057303A1
(de)
|
2004-11-26 |
2006-06-01 |
Merck Patent Gmbh |
Stabile Kristallmodifikationen von DOTAP Chlorid
|
EP1674081A1
(de)
*
|
2004-12-23 |
2006-06-28 |
KTB Tumorforschungsgesellschaft mbH |
Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
|
SG158155A1
(en)
|
2004-12-29 |
2010-01-29 |
Mannkind Corp |
Methods to bypass cd+4 cells in the induction of an immune response
|
JP4361545B2
(ja)
|
2005-05-09 |
2009-11-11 |
小野薬品工業株式会社 |
ProgrammedDeath1(PD−1)に対するヒトモノクローナル抗体および抗PD−1抗体単独または他の免疫療法と併用した癌治療方法
|
HUE026039T2
(en)
|
2005-07-01 |
2016-05-30 |
Squibb & Sons Llc |
Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
|
EP3611266B1
(en)
|
2005-08-23 |
2022-11-09 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
DE102005041616B4
(de)
|
2005-09-01 |
2011-03-17 |
Johannes-Gutenberg-Universität Mainz |
Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
|
EP1762575A1
(en)
|
2005-09-12 |
2007-03-14 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated antigens for diagnosis and therapy
|
WO2007107304A2
(en)
*
|
2006-03-17 |
2007-09-27 |
Novosom Ag |
An efficient method for loading amphoteric liposomes with nucleic acid active substances
|
US20120021042A1
(en)
*
|
2005-09-15 |
2012-01-26 |
Steffen Panzner |
Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
|
EP1994181A4
(en)
|
2006-02-27 |
2010-05-19 |
Univ Arizona |
IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
|
US20090304711A1
(en)
|
2006-09-20 |
2009-12-10 |
Drew Pardoll |
Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
|
DE102006060824B4
(de)
|
2006-12-21 |
2011-06-01 |
Johannes-Gutenberg-Universität Mainz |
Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
|
KR101523391B1
(ko)
|
2006-12-27 |
2015-05-27 |
에모리 유니버시티 |
감염 및 종양 치료를 위한 조성물 및 방법
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
US8140270B2
(en)
|
2007-03-22 |
2012-03-20 |
National Center For Genome Resources |
Methods and systems for medical sequencing analysis
|
WO2008147526A1
(en)
*
|
2007-05-23 |
2008-12-04 |
The Trustees Of The University Of Pennsylvania |
Targeted carriers for intracellular drug delivery
|
PL2170959T3
(pl)
|
2007-06-18 |
2014-03-31 |
Merck Sharp & Dohme |
Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
|
EP2060583A1
(en)
|
2007-10-23 |
2009-05-20 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated markers for diagnosis and therapy
|
NZ588183A
(en)
|
2008-03-24 |
2012-05-25 |
4Sc Discovery Gmbh |
Novel substituted imidazoquinolines
|
RU2530555C2
(ru)
|
2008-04-17 |
2014-10-10 |
ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН |
Стимуляция иммунного ответа энантиомерами катионных липидов
|
DE102008061522A1
(de)
|
2008-12-10 |
2010-06-17 |
Biontech Ag |
Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
|
AU2010223967B2
(en)
*
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
KR20140119197A
(ko)
|
2009-07-31 |
2014-10-08 |
에트리스 게엠베하 |
단백질 발현을 위한 비변형된 뉴클레오티드 및 변형된 뉴클레오티드의 조합을 가진 rna
|
CA2793846A1
(en)
*
|
2010-03-12 |
2011-09-15 |
The Regents Of The University Of California |
Triggered cargo release from nanoparticle stabilized liposomes
|
KR102315754B1
(ko)
|
2010-05-14 |
2021-10-22 |
더 제너럴 하스피톨 코포레이션 |
종양 특이적 신생항원을 확인하는 조성물 및 방법
|
AU2011308496A1
(en)
|
2010-10-01 |
2013-05-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
DE102011102734A1
(de)
|
2011-05-20 |
2012-11-22 |
WMF Württembergische Metallwarenfabrik Aktiengesellschaft |
Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
|
EP2771349B1
(en)
|
2011-09-16 |
2020-02-26 |
Iogenetics, LLC. |
Bioinformatic processes for determination of peptide binding
|
WO2013052523A1
(en)
|
2011-10-03 |
2013-04-11 |
modeRNA Therapeutics |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
US9579338B2
(en)
*
|
2011-11-04 |
2017-02-28 |
Nitto Denko Corporation |
Method of producing lipid nanoparticles for drug delivery
|
TR201904389T4
(tr)
*
|
2011-11-04 |
2019-04-22 |
Nitto Denko Corp |
Lipit nükleik asit partiküllerinin steril bir şekilde üretilmesine yönelik yöntem.
|
CA2859387A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
US20150030576A1
(en)
|
2012-01-10 |
2015-01-29 |
Moderna Therapeutics, Inc. |
Methods and compositions for targeting agents into and across the blood-brain barrier
|
WO2013124701A2
(en)
|
2012-02-20 |
2013-08-29 |
Universita' Degli Studi Di Milano |
New homo- and heterodimeric smac mimetic compounds as apoptosis inducers
|
US20130255281A1
(en)
|
2012-03-29 |
2013-10-03 |
General Electric Company |
System and method for cooling electrical components
|
WO2013151669A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
AU2013289939B2
(en)
|
2012-07-12 |
2018-08-09 |
Persimmune, Inc. |
Personalized cancer vaccines and adoptive immune cell therapies
|
CN104769112A
(zh)
|
2012-11-01 |
2015-07-08 |
菲克特生物科学股份有限公司 |
用于在细胞中表达蛋白质的方法和产品
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
EP2931319B1
(en)
|
2012-12-13 |
2019-08-21 |
ModernaTX, Inc. |
Modified nucleic acid molecules and uses thereof
|
EP2964234A4
(en)
|
2013-03-09 |
2016-12-07 |
Moderna Therapeutics Inc |
NON-TRANSLATED HETEROLOGOUS REGIONS FOR MRNA
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
EP2971165A4
(en)
|
2013-03-15 |
2016-11-23 |
Moderna Therapeutics Inc |
DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
|
WO2014144711A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
US11377470B2
(en)
|
2013-03-15 |
2022-07-05 |
Modernatx, Inc. |
Ribonucleic acid purification
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
US10138507B2
(en)
|
2013-03-15 |
2018-11-27 |
Modernatx, Inc. |
Manufacturing methods for production of RNA transcripts
|
US20160002667A1
(en)
*
|
2013-03-15 |
2016-01-07 |
Rush University Medical Center |
Pseudomonas exotoxins for cancer treatment
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
KR20230145545A
(ko)
|
2013-04-07 |
2023-10-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
개인맞춤화 신생물 백신을 위한 조성물 및 방법
|
WO2015014375A1
(en)
|
2013-07-30 |
2015-02-05 |
Biontech Ag |
Tumor antigens for determining cancer therapy
|
JP2016530294A
(ja)
|
2013-09-03 |
2016-09-29 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
キメラポリヌクレオチド
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US9925277B2
(en)
|
2013-09-13 |
2018-03-27 |
Modernatx, Inc. |
Polynucleotide compositions containing amino acids
|
EP3049065A1
(en)
|
2013-09-26 |
2016-08-03 |
BioNTech AG |
Particles comprising a shell with rna
|
US10385088B2
(en)
|
2013-10-02 |
2019-08-20 |
Modernatx, Inc. |
Polynucleotide molecules and uses thereof
|
US20160264614A1
(en)
|
2013-10-02 |
2016-09-15 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
WO2015058780A1
(en)
|
2013-10-25 |
2015-04-30 |
Biontech Ag |
Method and kit for determining whether a subject shows an immune response
|
WO2015085318A2
(en)
|
2013-12-06 |
2015-06-11 |
Moderna Therapeutics, Inc. |
Targeted adaptive vaccines
|
EP3053585A1
(en)
|
2013-12-13 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
EP3102262A1
(en)
|
2014-02-05 |
2016-12-14 |
BioNTech AG |
A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
|
BR112016024644A2
(pt)
|
2014-04-23 |
2017-10-10 |
Modernatx Inc |
vacinas de ácido nucleico
|
WO2015172843A1
(en)
|
2014-05-16 |
2015-11-19 |
Biontech Diagnostics Gmbh |
Methods and kits for the diagnosis of cancer
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
WO2016062323A1
(en)
|
2014-10-20 |
2016-04-28 |
Biontech Ag |
Methods and compositions for diagnosis and treatment of cancer
|
US11149278B2
(en)
|
2014-12-12 |
2021-10-19 |
Curevac Ag |
Artificial nucleic acid molecules for improved protein expression
|
SG11201704681QA
(en)
|
2014-12-30 |
2017-07-28 |
Curevac Ag |
Artificial nucleic acid molecules
|
WO2016155809A1
(en)
|
2015-03-31 |
2016-10-06 |
Biontech Rna Pharmaceuticals Gmbh |
Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
|